Prophylactic Photodynamic Therapy to Organ Transplant Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2008 by Bispebjerg Hospital.
Recruitment status was  Not yet recruiting
Information provided by:
Bispebjerg Hospital Identifier:
First received: August 15, 2006
Last updated: May 30, 2008
Last verified: May 2008
To evaluate a possible prophylactic efficacy of photodynamic therapy on the incidence of non-melanoma skin cancer, actinic keratoses, warts and keratoses in recently organ transplanted recipients.

Condition Intervention
Organ Transplants
Procedure: Photodynamic Therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind

Further study details as provided by Bispebjerg Hospital:

Estimated Enrollment: 50
Study Start Date: April 2009

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Organ transplant recipients.
  • Age 40 years or older.

Exclusion Criteria:

  • Patients younger than 40 years and older than 70 years.
  • Clinical signs of skin cancer, actinic keratoses or warts at the time of inclusion.
  • Previous photodynamic therapy to the skin areas investigated.
  • Pregnancy or breast feeding patients.
  • Patients with porphyria.
  • Patients with a tendency to produce hypertrophic scars or keloids.
  • Patients with known allergy to Metvix.
  • Patients who are not considered able to follow the treatment protocol (e.g. severely alcoholic patients, dementia patients, mentally ill patients etc.).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00365521

Contact: Merete Hædersdal, MD, PhD, DrMedSci +45 35316002

Bispebjerg Hospital Not yet recruiting
Copenhagen, Copenhagen NV, Denmark, 2400
Contact: Merete Hædersdal    +45 35 31 60 02   
Sponsors and Collaborators
Bispebjerg Hospital
Principal Investigator: Merete Hædersdal, MD, PhD, DrMedSci Bispebjerg Hospital
  More Information Identifier: NCT00365521     History of Changes
Other Study ID Numbers: KF-01-314759 
Study First Received: August 15, 2006
Last Updated: May 30, 2008
Health Authority: Denmark: Ministry of Health

Keywords provided by Bispebjerg Hospital:
Organ transplant patients receiving immunosuppressive therapy processed this record on May 26, 2016